A Multi-center, Randomized, Open-Label, Parallel-Group Study with LJPC-401 for the Treatment of Myocardial Iron Overload in Patients with Transfusion-Dependent Beta Thalassemia

a Jolla Pharmaceutical Company0 个研究点目标入组 100 人开始时间: 2017年12月11日最近更新: 2019年6月30日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 100

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

入选标准

•1. Patients = 14 years of age with transfusion-dependent beta thalassemia and must have been transfused within 1 month of randomisation.
•2. Two separate MRIs that both demonstrate cardiac T2* MRI from 6 to 35 msec (= 6 to = 35 msec) with no more than a 15% difference between the first (MRI 1) and second (MRI 2) reading. MRI 1 and MRI 2
•must be at least 3 weeks apart. MRI 1 may be a historical SOC cardiac
•T2* MRI performed within 12 months of randomisation.
•3. Patients must be receiving iron chelation therapy for a minimum of 1 year and be on a stable, appropriate dose of iron chelation therapy for a minimum of 8 weeks prior to randomisation and expected to remain stable during study participation.
•4. Female patients must be of non-childbearing potential, or using a highly effective method of contraception during participation in the study and for 30 days after the last dose of study drug. Highly effective methods of contraception are defined as those, alone or in combination, that result in a low failure rate when used consistently and correctly. These include: surgical sterility (vasectomy, bilateral tubal ligation, or hysterectomy); hormonal intrauterine device (IUD); hormonal intrauterine system (IUS), implants, or injections; consistent use of an approved oral contraceptive pill (combined progestin/estrogen pill or progestin-only pill); combined intravaginal or transdermal method; and abstinence.
•5. Female patients of childbearing potential must have a negative serum pregnancy test at Screening, negative pregnancy test predose on the first day study drug is administered, and negative pregnancy tests during the study.
•6. Male patients must be surgically sterile, or using a highly effective method of contraception during participation in the study and for 30 days after the last dose of study drug. Highly effective methods of contraception are defined as those, alone or in combination, that result in a low failure rate when used consistently and correctly.
•7. Patient must be willing and able to provide written informed consent and/or assent. Parent(s) or legal guardian(s) to patients younger than the local age of majority (ie, adult) is willing and able to provide
•informed consent and assist the patient in complying with all protocol requirements.
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 10
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 85
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 5

排除标准

•1. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from participating in the study.
•2. Pregnant or lactating women.
•3. Patients taking an immunosuppressive agent (excluding topical over-the-counter steroids, inhaled steroid medications, and nonsteroidal anti-inflammatory drugs) or have a planned surgery (excluding dental surgery or simple dermatologic procedures).
•4. Patients participating in an unapproved investigational drug or investigational therapeutic device study within 30 days prior to randomization, ie, there must be at least 30 days in between the last dose on a prior study and randomization on this trial.
•5. Patients with a concomitant disease, disability or condition, including laboratory abnormality and ECG findings, which may interfere with the conduct of the study, or which would, in the opinion of the investigator, pose an unacceptable risk to the patient in this study, including, but not limited to, clinically significant arrhythmias, alcohol dependency or abuse, drug dependency or abuse, or psychiatric disease.
•6. Patients who are unwilling or unable to comply with the study protocol requirements.
•7. Patients with known hepatitis B, hepatitis C who are being treated for a positive viral load or are noncompliant with their hepatitis medication.
•8. Known and active human immunodeficiency virus (HIV) infection.
•9. Patients with severe congestive heart failure (New York Heart Association [NYHA] = Class 4).
•10. Use of erythropoiesis stimulating agents in the past 3 months prior to study entry.
•11. History of allergic reaction to hepcidin or excipients.
•12. Contraindication to MRI scanning.

研究者

发起方

a Jolla Pharmaceutical Company

相似试验

进行中（未招募）

1 期

A multi-center clinical study to determine the effects of LJPC-401 on iron in the heart muscle in patients with beta-thalassemia who are treated with routine blood transfusionsTransfusion-dependent beta thalassemia with myocardial iron overloadMedDRA version: 20.0Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disorders

EUCTR2017-003372-31-CYa Jolla Pharmaceutical Company100

进行中（未招募）

1 期

EUCTR2017-003372-31-ITA JOLLA PHARMACEUTICAL COMPANY100

进行中（未招募）

1 期

EUCTR2017-003372-31-GRa Jolla Pharmaceutical Company100

进行中（未招募）

不适用

An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation TherapyMedDRA version: 9.1Level: LLTClassification code 10007113Term: Cancer of prostateProstate Cancer

EUCTR2007-006055-39-HUFerring Pharmaceuticals A/S540

进行中（未招募）

不适用

EUCTR2007-006055-39-BEFerring Pharmaceuticals A/S540